Orphan Drug - Global Market Outlook (2016-2022)                     

February 2017 | 148 pages | ID: O95674FBC21EN
Stratistics Market Research Consulting

Abstracts

According to Stratistics MRC, the Global Orphan Drug market is estimated at $145.89 million in 2016 and is expected to reach $265.63 million by 2022 growing at a CAGR of 10.5% from 2016 to 2022. Rising focus of big pharmaceutical companies on orphan drug improvement, increasing occurrence of rare diseases, government incentives for orphan medicine are some factors favouring the market growth. However, some factors such as high initial investment that leads to higher per patient treatment cost, reimbursement uncertainties and high cost of drug development are hindering the market. North America registered significant growth for the market during the forecast period due to rising healthcare spending, constructive government initiatives, growing occurrence of chronic diseases and small timeline required for orphan drug development.

Some of the key players in the market include Abbott Laboratories, AbbVie Inc., Alexion Pharmaceuticals, Amgen, Inc., Bayer Healthcare, Boehringer Ingelheim GmbH, Bristol Myers Squibb, Celgene Corporation, F. Hoffmann-La Roche AG, Genentech, Janssen Biotech, Inc.,

Johnson & Johnson, Merck & Co., Inc., Novartis, Pfizer Inc., Roche Holding AG, Sanofi Aventis and Vertex Pharmaceuticals.

Drug Types Covered:

• Biological orphan drugs
• Non-biological orphan drugs

Applications Covered:

• Blood-related disorders
• Nephrology
• Neurology
• Oncology
• Infectious diseases
• Cystic fibrosis
• Other Applications

Technologies Covered:

• DNA recombination
• Hybridoma and gene mapping
• Transgenic
• Other Technologies

Pharmacological classes Covered:

• Enzyme replacement
• Gene and chromosome expression
• Protein replacement

Indications Covered:

• Acute Myeloid Leukemia
• Duchenne Muscular Dystrophy
• Glioma
• Graft vs Host Disease
• Multiple Myeloma
• Non-Hodgkin Lymphoma
• Ovarian Cancer
• Pancreatic Cancer
• Renal Cell Carcinoma
• Other Indications

Regions Covered:

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• Italy
• UK
• Spain
• Rest of Europe
• Asia Pacific
• Japan
• China
• India
• Australia
• New Zealand
• Rest of Asia Pacific
• Rest of the World
• Middle East
• Brazil
• Argentina
• South Africa
• Egypt

What our report offers:

• Market share assessments for the regional and country level segments
• Market share analysis of the top industry players
• Strategic recommendations for the new entrants
• Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
  2.4.1 Data Mining
  2.4.2 Data Analysis
  2.4.3 Data Validation
  2.4.4 Research Approach
2.5 Research Sources
  2.5.1 Primary Research Sources
  2.5.2 Secondary Research Sources
  2.5.3 Assumptions

3 MARKET TREND ANALYSIS

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 Technology Analysis
3.8 Emerging Markets
3.9 Futuristic Market Scenario

4 PORTERS FIVE FORCE ANALYSIS

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 GLOBAL ORPHAN DRUGS MARKET, BY DRUG TYPE

5.1 Introduction
5.2 Biological orphan drugs
5.3 Non-biological orphan drugs

6 GLOBAL ORPHAN DRUGS MARKET, BY APPLICATION

6.1 Introduction
6.2 Blood-related disorders
6.3 Nephrology
6.4 Neurology
6.5 Oncology 6.6 Infectious diseases
6.7 Cystic fibrosis
6.8 Other Applications

7 GLOBAL ORPHAN DRUGS MARKET, BY TECHNOLOGY

7.1 Introduction
7.2 DNA recombination
7.3 Hybridoma and gene mapping
7.4 Transgenic
7.5 Other Technologies

8 GLOBAL ORPHAN DRUGS MARKET, BY PHARMACOLOGICAL CLASS

8.1 Introduction
8.2 Enzyme replacement
8.3 Gene and chromosome expression
8.4 Protein replacement

9 GLOBAL ORPHAN DRUGS MARKET, BY INDICATION

9.1 Introduction
9.2 Acute Myeloid Leukemia
9.3 Duchenne Muscular Dystrophy
9.4 Glioma
9.5 Graft vs Host Disease
9.6 Multiple Myeloma
9.7 Non-Hodgkin Lymphoma
9.8 Ovarian Cancer
9.9 Pancreatic Cancer
9.10 Renal Cell Carcinoma
9.11 Other Indications

10 GLOBAL ORPHAN DRUG MARKET, BY GEOGRAPHY

10.1 North America
  10.1.1 US
  10.1.2 Canada
  10.1.3 Mexico
10.2 Europe
  10.2.1 Germany
  10.2.2 France
  10.2.3 Italy
  10.2.4 UK
  10.2.5 Spain
  10.2.6 Rest of Europe
10.3 Asia Pacific
  10.3.1 Japan
  10.3.2 China
  10.3.3 India
  10.3.4 Australia
  10.3.5 New Zealand
  10.3.6 Rest of Asia Pacific
10.4 Rest of the World
  10.4.1 Middle East
  10.4.2 Brazil
  10.4.3 Argentina
  10.4.4 South Africa
  10.4.5 Egypt

11 KEY DEVELOPMENTS

11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies

12 COMPANY PROFILING

12.1 Abbott Laboratories
12.2 AbbVie Inc.
12.3 Alexion Pharmaceuticals
12.4 Amgen, Inc.
12.5 Bayer Healthcare
12.6 Boehringer Ingelheim GmbH
12.7 Bristol Myers Squibb
12.8 Celgene Corporation
12.9 F. Hoffmann-La Roche AG
12.10 Genentech
12.11 Janssen Biotech, Inc.
12.12 Johnson & Johnson
12.13 Merck & Co., Inc.
12.14 Novartis
12.15 Pfizer Inc.
12.16 Roche Holding AG
12.17 Sanofi Aventis
12.18 Vertex Pharmaceuticals

List Of Tables

LIST OF TABLES

Table 1 Global Orphan Drug Market Outlook, By Region (2014-2022) ($MN)
Table 2 Global Orphan Drug Market Outlook, By Drug Type (2014-2022) ($MN)
Table 3 Global Orphan Drug Market Outlook, By Biological orphan drugs (2014-2022) ($MN)
Table 4 Global Orphan Drug Market Outlook, By Non-biological orphan drugs (2014-2022) ($MN)
Table 5 Global Orphan Drug Market Outlook, By Application (2014-2022) ($MN)
Table 6 Global Orphan Drug Market Outlook, By Blood-related disorders (2014-2022) ($MN)
Table 7 Global Orphan Drug Market Outlook, By Nephrology (2014-2022) ($MN)
Table 8 Global Orphan Drug Market Outlook, By Neurology (2014-2022) ($MN)
Table 9 Global Orphan Drug Market Outlook, By Oncology (2014-2022) ($MN)
Table 10 Global Orphan Drug Market Outlook, By Infectious diseases (2014-2022) ($MN)
Table 11 Global Orphan Drug Market Outlook, By Cystic fibrosis (2014-2022) ($MN)
Table 12 Global Orphan Drug Market Outlook, By Other Applications (2014-2022) ($MN)
Table 13 Global Orphan Drug Market Outlook, By Technology (2014-2022) ($MN)
Table 14 Global Orphan Drug Market Outlook, By DNA recombination (2014-2022) ($MN)
Table 15 Global Orphan Drug Market Outlook, By Hybridoma and gene mapping (2014-2022) ($MN)
Table 16 Global Orphan Drug Market Outlook, By Transgenic (2014-2022) ($MN)
Table 17 Global Orphan Drug Market Outlook, By Other Technologies (2014-2022) ($MN)
Table 18 Global Orphan Drug Market Outlook, By Pharmacological class (2014-2022) ($MN)
Table 19 Global Orphan Drug Market Outlook, By Enzyme replacement (2014-2022) ($MN)
Table 20 Global Orphan Drug Market Outlook, By Gene and chromosome expression (2014-2022) ($MN)
Table 21 Global Orphan Drug Market Outlook, By Protein replacement (2014-2022) ($MN)
Table 22 Global Orphan Drug Market Outlook, By Indication (2014-2022) ($MN)
Table 23 Global Orphan Drug Market Outlook, By Acute Myeloid Leukemia (2014-2022) ($MN)
Table 24 Global Orphan Drug Market Outlook, By Duchenne Muscular Dystrophy (2014-2022) ($MN)
Table 25 Global Orphan Drug Market Outlook, By Glioma (2014-2022) ($MN)
Table 26 Global Orphan Drug Market Outlook, By Graft vs Host Disease (2014-2022) ($MN)
Table 27 Global Orphan Drug Market Outlook, By Multiple Myeloma (2014-2022) ($MN)
Table 28 Global Orphan Drug Market Outlook, By Non-Hodgkin Lymphoma (2014-2022) ($MN)
Table 29 Global Orphan Drug Market Outlook, By Ovarian Cancer (2014-2022) ($MN)
Table 30 Global Orphan Drug Market Outlook, By Pancreatic Cancer (2014-2022) ($MN)
Table 31 Global Orphan Drug Market Outlook, By Renal Cell Carcinoma (2014-2022) ($MN)
Table 32 Global Orphan Drug Market Outlook, By Other Indications (2014-2022) ($MN)
Table 33 North America Orphan Drug Market Outlook, By Country (2014-2022) ($MN)
Table 34 North America Orphan Drug Market Outlook, By Drug Type (2014-2022) ($MN)
Table 35 North America Orphan Drug Market Outlook, By Biological orphan drugs (2014-2022) ($MN)
Table 36 North America Orphan Drug Market Outlook, By Non-biological orphan drugs (2014-2022) ($MN)
Table 37 North America Orphan Drug Market Outlook, By Application (2014-2022) ($MN)
Table 38 North America Orphan Drug Market Outlook, By Blood-related disorders (2014-2022) ($MN)
Table 39 North America Orphan Drug Market Outlook, By Nephrology (2014-2022) ($MN)
Table 40 North America Orphan Drug Market Outlook, By Neurology (2014-2022) ($MN)
Table 41 North America Orphan Drug Market Outlook, By Oncology (2014-2022) ($MN)
Table 42 North America Orphan Drug Market Outlook, By Infectious diseases (2014-2022) ($MN)
Table 43 North America Orphan Drug Market Outlook, By Cystic fibrosis (2014-2022) ($MN)
Table 44 North America Orphan Drug Market Outlook, By Other Applications (2014-2022) ($MN)
Table 45 North America Orphan Drug Market Outlook, By Technology (2014-2022) ($MN)
Table 46 North America Orphan Drug Market Outlook, By DNA recombination (2014-2022) ($MN)
Table 47 North America Orphan Drug Market Outlook, By Hybridoma and gene mapping (2014-2022) ($MN)
Table 48 North America Orphan Drug Market Outlook, By Transgenic (2014-2022) ($MN)
Table 49 North America Orphan Drug Market Outlook, By Other Technologies (2014-2022) ($MN)
Table 50 North America Orphan Drug Market Outlook, By Pharmacological class (2014-2022) ($MN)
Table 51 North America Orphan Drug Market Outlook, By Enzyme replacement (2014-2022) ($MN)
Table 52 North America Orphan Drug Market Outlook, By Gene and chromosome expression (2014-2022) ($MN)
Table 53 North America Orphan Drug Market Outlook, By Protein replacement (2014-2022) ($MN)
Table 54 North America Orphan Drug Market Outlook, By Indication (2014-2022) ($MN)
Table 55 North America Orphan Drug Market Outlook, By Acute Myeloid Leukemia (2014-2022) ($MN)
Table 56 North America Orphan Drug Market Outlook, By Duchenne Muscular Dystrophy (2014-2022) ($MN)
Table 57 North America Orphan Drug Market Outlook, By Glioma (2014-2022) ($MN)
Table 58 North America Orphan Drug Market Outlook, By Graft vs Host Disease (2014-2022) ($MN)
Table 59 North America Orphan Drug Market Outlook, By Multiple Myeloma (2014-2022) ($MN)
Table 60 North America Orphan Drug Market Outlook, By Non-Hodgkin Lymphoma (2014-2022) ($MN)
Table 61 North America Orphan Drug Market Outlook, By Ovarian Cancer (2014-2022) ($MN)
Table 62 North America Orphan Drug Market Outlook, By Pancreatic Cancer (2014-2022) ($MN)
Table 63 North America Orphan Drug Market Outlook, By Renal Cell Carcinoma (2014-2022) ($MN)
Table 64 North America Orphan Drug Market Outlook, By Other Indications (2014-2022) ($MN)
Table 65 Europe Orphan Drug Market Outlook, By Country (2014-2022) ($MN)
Table 66 Europe Orphan Drug Market Outlook, By Drug Type (2014-2022) ($MN)
Table 67 Europe Orphan Drug Market Outlook, By Biological orphan drugs (2014-2022) ($MN)
Table 68 Europe Orphan Drug Market Outlook, By Non-biological orphan drugs (2014-2022) ($MN)
Table 69 Europe Orphan Drug Market Outlook, By Application (2014-2022) ($MN)
Table 70 Europe Orphan Drug Market Outlook, By Blood-related disorders (2014-2022) ($MN)
Table 71 Europe Orphan Drug Market Outlook, By Nephrology (2014-2022) ($MN)
Table 72 Europe Orphan Drug Market Outlook, By Neurology (2014-2022) ($MN)
Table 73 Europe Orphan Drug Market Outlook, By Oncology (2014-2022) ($MN)
Table 74 Europe Orphan Drug Market Outlook, By Infectious diseases (2014-2022) ($MN)
Table 75 Europe Orphan Drug Market Outlook, By Cystic fibrosis (2014-2022) ($MN)
Table 76 Europe Orphan Drug Market Outlook, By Other Applications (2014-2022) ($MN)
Table 77 Europe Orphan Drug Market Outlook, By Technology (2014-2022) ($MN)
Table 78 Europe Orphan Drug Market Outlook, By DNA recombination (2014-2022) ($MN)
Table 79 Europe Orphan Drug Market Outlook, By Hybridoma and gene mapping (2014-2022) ($MN)
Table 80 Europe Orphan Drug Market Outlook, By Transgenic (2014-2022) ($MN)
Table 81 Europe Orphan Drug Market Outlook, By Other Technologies (2014-2022) ($MN)
Table 82 Europe Orphan Drug Market Outlook, By Pharmacological class (2014-2022) ($MN)
Table 83 Europe Orphan Drug Market Outlook, By Enzyme replacement (2014-2022) ($MN)
Table 84 Europe Orphan Drug Market Outlook, By Gene and chromosome expression (2014-2022) ($MN)
Table 85 Europe Orphan Drug Market Outlook, By Protein replacement (2014-2022) ($MN)
Table 86 Europe Orphan Drug Market Outlook, By Indication (2014-2022) ($MN)
Table 87 Europe Orphan Drug Market Outlook, By Acute Myeloid Leukemia (2014-2022) ($MN)
Table 88 Europe Orphan Drug Market Outlook, By Duchenne Muscular Dystrophy (2014-2022) ($MN)
Table 89 Europe Orphan Drug Market Outlook, By Glioma (2014-2022) ($MN)
Table 90 Europe Orphan Drug Market Outlook, By Graft vs Host Disease (2014-2022) ($MN)
Table 91 Europe Orphan Drug Market Outlook, By Multiple Myeloma (2014-2022) ($MN)
Table 92 Europe Orphan Drug Market Outlook, By Non-Hodgkin Lymphoma (2014-2022) ($MN)
Table 93 Europe Orphan Drug Market Outlook, By Ovarian Cancer (2014-2022) ($MN)
Table 94 Europe Orphan Drug Market Outlook, By Pancreatic Cancer (2014-2022) ($MN)
Table 95 Europe Orphan Drug Market Outlook, By Renal Cell Carcinoma (2014-2022) ($MN)
Table 96 Europe Orphan Drug Market Outlook, By Other Indications (2014-2022) ($MN)
Table 97 Asia Pacific Orphan Drug Market Outlook, By Country (2014-2022) ($MN)
Table 98 Asia Pacific Orphan Drug Market Outlook, By Drug Type (2014-2022) ($MN)
Table 99 Asia Pacific Orphan Drug Market Outlook, By Biological orphan drugs (2014-2022) ($MN)
Table 100 Asia Pacific Orphan Drug Market Outlook, By Non-biological orphan drugs (2014-2022) ($MN)
Table 101 Asia Pacific Orphan Drug Market Outlook, By Application (2014-2022) ($MN)
Table 102 Asia Pacific Orphan Drug Market Outlook, By Blood-related disorders (2014-2022) ($MN)
Table 103 Asia Pacific Orphan Drug Market Outlook, By Nephrology (2014-2022) ($MN)
Table 104 Asia Pacific Orphan Drug Market Outlook, By Neurology (2014-2022) ($MN)
Table 105 Asia Pacific Orphan Drug Market Outlook, By Oncology (2014-2022) ($MN)
Table 106 Asia Pacific Orphan Drug Market Outlook, By Infectious diseases (2014-2022) ($MN)
Table 107 Asia Pacific Orphan Drug Market Outlook, By Cystic fibrosis (2014-2022) ($MN)
Table 108 Asia Pacific Orphan Drug Market Outlook, By Other Applications (2014-2022) ($MN)
Table 109 Asia Pacific Orphan Drug Market Outlook, By Technology (2014-2022) ($MN)
Table 110 Asia Pacific Orphan Drug Market Outlook, By DNA recombination (2014-2022) ($MN)
Table 111 Asia Pacific Orphan Drug Market Outlook, By Hybridoma and gene mapping (2014-2022) ($MN)
Table 112 Asia Pacific Orphan Drug Market Outlook, By Transgenic (2014-2022) ($MN)
Table 113 Asia Pacific Orphan Drug Market Outlook, By Other Technologies (2014-2022) ($MN)
Table 114 Asia Pacific Orphan Drug Market Outlook, By Pharmacological class (2014-2022) ($MN)
Table 115 Asia Pacific Orphan Drug Market Outlook, By Enzyme replacement (2014-2022) ($MN)
Table 116 Asia Pacific Orphan Drug Market Outlook, By Gene and chromosome expression (2014-2022) ($MN)
Table 117 Asia Pacific Orphan Drug Market Outlook, By Protein replacement (2014-2022) ($MN)
Table 118 Asia Pacific Orphan Drug Market Outlook, By Indication (2014-2022) ($MN)
Table 119 Asia Pacific Orphan Drug Market Outlook, By Acute Myeloid Leukemia (2014-2022) ($MN)
Table 120 Asia Pacific Orphan Drug Market Outlook, By Duchenne Muscular Dystrophy (2014-2022) ($MN)
Table 121 Asia Pacific Orphan Drug Market Outlook, By Glioma (2014-2022) ($MN)
Table 122 Asia Pacific Orphan Drug Market Outlook, By Graft vs Host Disease (2014-2022) ($MN)
Table 123 Asia Pacific Orphan Drug Market Outlook, By Multiple Myeloma (2014-2022) ($MN)
Table 124 Asia Pacific Orphan Drug Market Outlook, By Non-Hodgkin Lymphoma (2014-2022) ($MN)
Table 125 Asia Pacific Orphan Drug Market Outlook, By Ovarian Cancer (2014-2022) ($MN)
Table 126 Asia Pacific Orphan Drug Market Outlook, By Pancreatic Cancer (2014-2022) ($MN)
Table 127 Asia Pacific Orphan Drug Market Outlook, By Renal Cell Carcinoma (2014-2022) ($MN)
Table 128 Asia Pacific Orphan Drug Market Outlook, By Other Indications (2014-2022) ($MN)
Table 129 RoW Orphan Drug Market Outlook, By Country (2014-2022) ($MN)
Table 130 RoW Orphan Drug Market Outlook, By Drug Type (2014-2022) ($MN)
Table 131 RoW Orphan Drug Market Outlook, By Biological orphan drugs (2014-2022) ($MN)
Table 132 RoW Orphan Drug Market Outlook, By Non-biological orphan drugs (2014-2022) ($MN)
Table 133 RoW Orphan Drug Market Outlook, By Application (2014-2022) ($MN)
Table 134 RoW Orphan Drug Market Outlook, By Blood-related disorders (2014-2022) ($MN)
Table 135 RoW Orphan Drug Market Outlook, By Nephrology (2014-2022) ($MN)
Table 136 RoW Orphan Drug Market Outlook, By Neurology (2014-2022) ($MN)
Table 137 RoW Orphan Drug Market Outlook, By Oncology (2014-2022) ($MN)
Table 138 RoW Orphan Drug Market Outlook, By Infectious diseases (2014-2022) ($MN)
Table 139 RoW Orphan Drug Market Outlook, By Cystic fibrosis (2014-2022) ($MN)
Table 140 RoW Orphan Drug Market Outlook, By Other Applications (2014-2022) ($MN)
Table 141 RoW Orphan Drug Market Outlook, By Technology (2014-2022) ($MN)
Table 142 RoW Orphan Drug Market Outlook, By DNA recombination (2014-2022) ($MN)
Table 143 RoW Orphan Drug Market Outlook, By Hybridoma and gene mapping (2014-2022) ($MN)
Table 144 RoW Orphan Drug Market Outlook, By Transgenic (2014-2022) ($MN)
Table 145 RoW Orphan Drug Market Outlook, By Other Technologies (2014-2022) ($MN)
Table 146 RoW Orphan Drug Market Outlook, By Pharmacological class (2014-2022) ($MN)
Table 147 RoW Orphan Drug Market Outlook, By Enzyme replacement (2014-2022) ($MN)
Table 148 RoW Orphan Drug Market Outlook, By Gene and chromosome expression (2014-2022) ($MN)
Table 149 RoW Orphan Drug Market Outlook, By Protein replacement (2014-2022) ($MN)
Table 150 RoW Orphan Drug Market Outlook, By Indication (2014-2022) ($MN)
Table 151 RoW Orphan Drug Market Outlook, By Acute Myeloid Leukemia (2014-2022) ($MN)
Table 152 RoW Orphan Drug Market Outlook, By Duchenne Muscular Dystrophy (2014-2022) ($MN)
Table 153 RoW Orphan Drug Market Outlook, By Glioma (2014-2022) ($MN)
Table 154 RoW Orphan Drug Market Outlook, By Graft vs Host Disease (2014-2022) ($MN)
Table 155 RoW Orphan Drug Market Outlook, By Multiple Myeloma (2014-2022) ($MN)
Table 156 RoW Orphan Drug Market Outlook, By Non-Hodgkin Lymphoma (2014-2022) ($MN)
Table 157 RoW Orphan Drug Market Outlook, By Ovarian Cancer (2014-2022) ($MN)
Table 158 RoW Orphan Drug Market Outlook, By Pancreatic Cancer (2014-2022) ($MN)
Table 159 RoW Orphan Drug Market Outlook, By Renal Cell Carcinoma (2014-2022) ($MN)
Table 160 RoW Orphan Drug Market Outlook, By Other Indications (2014-2022) ($MN)